Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naïve Crohn's disease cohort with penetrating disease, -ostomies and sarcopenia.

Ther Adv Chronic Dis · 2023 · PMC10434845 · PMID 37601038

Europe PMC DOI

hedged sentence

0.0820

closest p · 1.6× alpha

0.0820

boldest claim

The sentences

of borderline significancep = 0.082so close (0.05 < p ≤ 0.1)

Sarcopenia was of borderline significance at 12 months ( p = 0.082) and 18 months ( p = 0.058), whereby sarcopenic patients were 3.3 times more likely to discontinue ustekinumab by 18 months.

also in 446 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.